About Marinus

Marinus is committed to improving the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders. We are developing an investigational drug, ganaxolone, which is an innovative and much needed potential treatment option for children and adults.

Ganaxolone, our leading drug candidate, is designed to exhibit anti-epileptic, anxiolytic, antidepressant, and sedative activity by virtue of its GABAA receptor modulating properties. Ganaxolone is being developed in intravenous (IV) and oral formulations intended to maximize therapeutic reach to adult and pediatric patient populations in both acute and chronic care settings where there is a mechanistic rationale for ganaxolone to provide a benefit.


Our Mission

At Marinus, we use a strong scientific rationale, determination, and expertise to embrace the challenge of developing treatments in rare epilepsy and neuropsychiatric disorders. We are committed to our patients, physicians, and epilepsy community, as we plan our path forward to providing much needed options for patients.

Our Vision

Our vision is to strengthen the value of ganaxolone as a first-in-class innovative therapy for children and adults afflicted with disorders affecting the central nervous system.


Currently, ganaxolone is being studied in 5 different rare epilepsy and neuropsychiatric indications.